Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Double-Blind, Placebo-Controlled, Ascending, Single-Dose, Safety, Tolerability and Pharmacokinetic Study of Bisnorcymserine (BNC), a Highly Selective Inhibitor of Butyrylcholinesterase, in Healthy Adult Volunteers

NCT01747213 is registered in ClinicalTrials.gov with National Institute on Aging (NIA) as lead sponsor.

NCT NCT01747213
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01747213 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Double-Blind, Placebo-Controlled, Ascending, Single-Dose, Safety, Tolerability and Pharmacokinetic Study of Bisnorcymserine (BNC), a Highly Selective Inhibitor of Butyrylcholinesterase, in Healthy Adult Volunteers
Lead sponsor
National Institute on Aging (NIA)
Phase
Phase 1
Overall status
Completed
Start date
January 29, 2013
Completion date
January 8, 2019
Enrollment
75 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers